# Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

> **NCT03746912** · — · NO_LONGER_AVAILABLE · sponsor: **Daiichi Sankyo**

## Conditions studied

- Acute Myeloid Leukemia With Gene Mutations

## Interventions

- **DRUG:** Quizartinib Dihydrochloride

## Key facts

- **NCT ID:** NCT03746912
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746912, "Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03746912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*